Exploring the VISTA of microglia:immune checkpoints in CNS inflammation by Borggrewe, Malte et al.
 
 
 University of Groningen
Exploring the VISTA of microglia
Borggrewe, Malte; Kooistra, Susanne M; Noelle, Randolph J; Eggen, Bart J L; Laman, Jon D
Published in:
Journal of Molecular Medicine
DOI:
10.1007/s00109-020-01968-x
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Borggrewe, M., Kooistra, S. M., Noelle, R. J., Eggen, B. J. L., & Laman, J. D. (2020). Exploring the VISTA
of microglia: immune checkpoints in CNS inflammation. Journal of Molecular Medicine, 98(10), 1415-1430.
https://doi.org/10.1007/s00109-020-01968-x
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
REVIEW
Exploring the VISTA of microglia: immune checkpoints in CNS
inflammation
Malte Borggrewe1 & Susanne M. Kooistra1 & Randolph J. Noelle2 & Bart J. L. Eggen1 & Jon D. Laman1
Received: 24 June 2020 /Revised: 13 August 2020 /Accepted: 17 August 2020
# The Author(s) 2020
Abstract
Negative checkpoint regulators (NCR) are intensely pursued as targets to modulate the immune response in cancer and autoim-
munity. A large variety of NCR is expressed by central nervous system (CNS)-resident cell types and is associated with CNS
homeostasis, interactions with peripheral immunity and CNS inflammation and disease. Immunotherapy blocking NCR affects
the CNS as patients can develop neurological issues including encephalitis and multiple sclerosis (MS). How these treatments
affect the CNS is incompletely understood, since expression and function of NCR in the CNS are only beginning to be
unravelled. V-type immunoglobulin-like suppressor of T cell activation (VISTA) is an NCR that is expressed primarily in the
haematopoietic system bymyeloid and T cells. VISTA regulates T cell quiescence and activation and has a variety of functions in
myeloid cells including efferocytosis, cytokine response and chemotaxis. In the CNS, VISTA is predominantly expressed by
microglia and macrophages of the CNS. In this review, we summarize the role of NCR in the CNS during health and disease. We
highlight expression of VISTA across cell types and CNS diseases and discuss the function of VISTA in microglia and during
CNS ageing, inflammation and neurodegeneration. Understanding the role of VISTA and other NCR in the CNS is important
considering the adverse effects of immunotherapy on the CNS, and in view of their therapeutic potential in CNS disease.
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Introduction
Immune checkpoints are critical in maintaining the balance
between protective immune responses of appropriate magni-
tude versus excessive inflammation with undue tissue damage
and autoimmune disease. Co-stimulatory and co-inhibitory
receptors provide T cells with activating or suppressing sig-
nals, respectively, and a disruption of this balance can lead to
autoimmunity or prevent specific immune responses.
Negative checkpoint regulators (NCR) are receptors that pro-
vide co-inhibitory signals to T cells, which lead to inhibition
of T cell activation. Targeting immune checkpoints and
particularly NCR are intensely pursued as therapeutic targets
for cancer and autoimmunity. Blocking NCR enhances anti-
tumour immunity, whereas enhancing NCR signalling offers a
strategy to alleviate autoimmunity. Studies mainly focus on
NCR biology in cancer and peripheral immunity; however,
multiple NCR are also expressed by central nervous system
(CNS)-resident cell types including neurons, oligodendro-
cytes, astrocytes and microglia [1]. Expression of most NCR
in the CNS is upregulated or induced during inflammation [1].
A subset of cancer patients develops neurological adverse
effects after NCR treatment including encephalitis and multi-
ple sclerosis (MS) [1, 2], demonstrating that NCR modulation
can affect the CNS. Inhibition of NCR has proven tomount an
anti-tumour response in certain types of CNS-associated hu-
man tumours [3, 4]. Furthermore, NCR blockade exacerbates
CNS autoimmunity such as experimental autoimmune en-
cephalomyelitis (EAE), a mouse model for MS [5]. Detailed
clinical studies assessing the effectiveness of modulating
NCR in CNS inflammation, ageing and neurodegeneration
are lacking.
V-type immunoglobulin domain-containing suppressor of
T cell activation (VISTA) is anNCR predominantly expressed
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by myeloid cells and T cells [6]. In contrast to other NCR,
VISTA is expressed on naïve T cells, where it is involved in
maintaining T cell quiescence [7] and expression is reduced
upon T cell activation. VISTA is also distinct from other NCR
because it has a wide diversity of functions in myeloid cells,
likely due to its role as a receptor and a ligand. In myeloid
cells, VISTA is involved in the uptake of apoptotic cells
(efferocytosis) [8], cytokine production [9, 10] and chemotax-
is [11]. In the CNS, VISTA is expressed by microglia and to a
lesser extent by endothelial cells [12]. Deletion of VISTA
exacerbates autoimmunity in mice including EAE [13]. The
functions of VISTA in the CNS during health and disease are
only beginning to be unravelled. As VISTA can be exploited
as a therapeutic target for cancer and autoimmune diseases, it
is conceivable that VISTAmay offer a novel therapeutic target
for CNS inflammation and disease.
In this review, current knowledge of VISTA and other
immune checkpoints in the CNS and particularly in microglia
are summarized. The potential function of VISTA in microg-
lia and during CNS homeostasis and disease are discussed.
Based on published RNA-sequencing studies, we provide
novel data on VISTA expression in the CNS during health
and multiple diseases including neurodegeneration, neuroin-
flammation, cancer and stroke.
VISTA expression and function
VISTA (also known as PD-1H [14], DD1a [8], Dies1 [15],
Gi24 [16], C10orf54, Vsir, B7H5 and 4632428N05Rik) is an
NCR that is expressed in multiple tissues at varying levels.
Multiple counterreceptors have been proposed, but not proven
beyond doubt. Mainly, immune cells express VISTA on
which it acts as both a receptor and a ligand. This dual role
and broad expression point towards multiple functions of
VISTA, which are discussed in this section.
VISTA structure and binding partners
VISTA is a transmembrane protein that contains an immuno-
globulin variable (IgV)-like fold and shares similarities with
B7 family members PD1, PDL1, CD28 and CTLA4 [17]. The
extracellular domain of VISTA contains four conserved cys-
teines that are not present in other B7 family members [17].
Across species, VISTA is highly conserved with 96% identi-
cal protein sequence comparing human to other primates
(rhesus macaque, cynomolgus monkey, common marmoset)
and 77% between human and mouse (unpublished). The
VISTA gene is located on chromosome 10 within the intronic
region of Cadherin23 (CDH23). Of note, regulation of VISTA
expression seems to be independent of CDH23 expression
[12].
Although the counterreceptor of VISTA remains elusive,
multiple candidate binding partners have been proposed:
VSIG3/IGSF11 [17, 18], VISTA itself through homophilic
interaction [8] and PSGL1 [19]. VSIG3 binds to VISTA in
ELISA assays [17, 18], and plate-bound VSIG3 inhibits anti-
CD3-induced cytokine secretion by T cells [18]. However,
evidence for functional cellular interactions through VISTA
and VSIG3 in vitro and particularly in vivo is lacking. A
homophilic VISTA interaction between apoptotic cells and
macrophages has been suggested to be necessary for facilitat-
ing uptake of apoptotic cells [8]. However, this homotypic
binding could not be replicated in another study [19]. In this
study, PSGL1 was proposed as a binding partner via histidine
residues within the extracellular domain of VISTA [19].
Binding of PSGL1 and VISTA leads to inhibition of T cell
activation and only occurs at acidic pH in vitro and in vivo
(pH 6.0) [19]. Hence, binding of VISTA to PSGL1 selectively
occurs in acidic environments, e.g. theoretically provided by
tumours and inflammation [19].
It is possible that VISTA has multiple binding partners, but
additional evidence and replication studies will be necessary
to unequivocally demonstrate functional binding of VISTA to
one or more of these potential counterreceptors.
VISTA expression across tissues and cell types
VISTA mRNA is expressed in multiple organs and tissues
including thymus, spleen, heart, kidney, lung, bone marrow
and the brain [6]. Predominantly, the hematopoietic compart-
ment expresses VISTA with highest levels in myeloid cells
(monocytes, macrophages, dendritic cells), neutrophils,
followed by naïve CD4+ and CD8+ T cells, as well as regula-
tory Foxp3+ T cells [6, 14, 20]. Whereas expression of other
NCR is increased upon T cell activation, VISTA is constitu-
tively expressed on resting T cells. VISTA expression in other
hematopoietic cell types is detectable but low, including NK
cells, thymocytes and plasma cells, whereas no VISTA ex-
pression is observed in B cells [6, 14, 20].
Of note, VISTA expression is not restricted to the cell
surface, but is also observed in high levels intracellularly in
myeloid cells [20]. Here, it colocalizes with markers for early
endosomes (EEA-1) and recycling endosomes (Rab-11) [20],
suggesting that VISTA is actively recycled and/or has other
functions in the cytoplasm.
Several studies demonstrated expression of VISTA in var-
ious types of cancer including gastric carcinoma [21], colo-
rectal carcinoma [22, 23], hepatocellular carcinoma [24],
ovarian and endometrial cancer [25], prostate cancer [26],
pancreatic cancer and melanoma [27]. In some types of can-
cer, VISTA is expressed by cancer cells themselves, including
gastric, ovarian and endometrial tumours [21, 25]. However,
VISTA expression is predominantly found on myeloid-
J Mol Med
derived suppressor cells (MDSC) in the tumour microenviron-
ment [28–31]. In MDSC, VISTA expression is induced by
hypoxic tumour environments via hypoxia-inducible factor
(HIF)-1a [23]. Moreover, VISTA expression is induced in
apoptotic cells as a downstream target of p53 and is required
for engulfment by phagocytes [8]. VISTA is also involved in
differentiation as reducing VISTA expression using siRNA or
miRNA-125b inhibits the differentiation of mouse embryonic
stem cells [15, 32] and preadipocytes [33].
VISTA as a negative checkpoint regulator
Multiple studies have demonstrated that VISTA inhibits T cell
activation and therefore functions as an NCR. VISTA-Ig fu-
sion protein or VISTA-overexpressing A20 cells both reduce
proliferation and cytokine production (Il2 and Ifng) in oval-
bumin (OVA) or anti-CD3-stimulated T cells in vitro [6].
Furthermore, blocking VISTA in mice using an antagonistic
anti-VISTA antibody (clone 13F3) increases T cell prolifera-
tion in response to OVA and exacerbates the development of
EAE, a model for MS [6]. Concomitantly, targeting VISTA
on T cells in mice using an agonistic anti-VISTA antibody
(clone MH5A or 8G8) protects mice from graft-versus-host
disease GvHD [14], hepatitis [34], lupus [7, 35], psoriasis [7]
and arthritis [7]. This protection fromGvHD is independent of
host cells [14] and is due to engagement of VISTA on donor T
cells, inhibiting their activation [7, 36].
In addition to inhibition of T cell activation, VISTA is also
involved in T cell differentiation and expansion. In GvHD, for
example, activation of VISTA on donor T cells expands reg-
ulatory T cells (Tregs) [14]. Concordantly, T cells in generic
VISTA knockout (KO) mice exhibit a reduced ability to form
iTregs [37]. The generation of natural Tregs, however, is not
impaired [37]. The iTregs of generic VISTA KO mice are
more prone to conversion into T helper 17 (Th17) and Th1
cells during inflammation compared to wild-type iTregs [37].
This overall reduction in iTreg formation and induction of Th1
and Th17 cells supports the notion of a more reactive T cell
compartment in VISTA KO mice. It is likely that this reactiv-
ity is caused by both intrinsic effects of VISTA deficiency in T
cells, and indirect effects of an altered cytokine profile and
depletion of VISTA in other cell types (e.g. dendritic cells,
DC). Consistent with this argument, DC in VISTA KO mice
produce more Il23, leading to augmented Il17a production by
Th17 and γδ T cells, resulting in the exacerbation of
psoriasiform plaques in mice induced by imiquimod [38].
In contrast to other NCR which are expressed upon T cell
activation, VISTA is constitutively expressed on resting T
cells, suggesting distinct functionalities. Underscoring this
non-redundant role of VISTA, double KO of VISTA and
PD1 significantly increases T cell responses to foreign anti-
gens and exacerbates EAE compared with VISTA or PD1
single KO mice [39]. Detailed analysis of the T cell compart-
ment in VISTA KO mice using single-cell transcriptomic and
epigenetic approaches demonstrates that VISTA is crucial for
maintaining naïve T cell quiescence [7]. Therefore, VISTA
regulates T cell tolerance before activation occurs, whereas
other NCR such as CTLA4 and PD1 only act after T cell
activation to inhibit priming and effector functions. VISTA
is the first known NCR that acts at such an early stage in the
T cell activation cascade and hence offers a novel, non-
redundant target for therapeutic interventions [7].
VISTA in myeloid cell biology
VISTA was initially discovered as an NCR, but since then, a
role for VISTA in a variety of other functions in myeloid cells
has been proposed, including cytokine response, chemotaxis
and efferocytosis.
In multiple mouse models of inflammation, VISTA KO is
associated with an increase in pro-inflammatory cytokines
[38, 40–42]. These cytokines derive from T cells and myeloid
cells. In a psoriasis mouse model, for example, VISTA KO
enhances the production of Il23 by DCs [38]. Surprisingly,
overexpression of VISTA in human monocytes in vitro leads
to spontaneous cytokine production (TNF, IL1β) on mRNA
[9] and protein level [10]. It is unclear whether these opposing
findings are due to differences between species (human versus
mouse), or because of distinct approaches of studying VISTA
(KO versus overexpression). Nonetheless, these studies dem-
onstrate that VISTA is involved in the cytokine response of
myeloid cells.
Emerging evidence suggests that VISTA is involved in
chemotaxis and migration through direct and indirect signal-
ling in myeloid cells. In VISTA KO mice, elevated levels of
inflammatory cytokines and chemokines such as Ccl2
(MCP1) are observed in the lung, which is associated with
the development of experimental asthma [41]. Ccl2 is a
chemoattractant for monocytes, and thus, VISTA may indi-
rectly regulate the recruitment of monocytes. VISTA also di-
rectly regulates monocyte chemotaxis, since blocking VISTA
on monocytes using an antagonistic antibody (clone 13F3)
enhances their migration ability [11]. Concordantly, expres-
sion of the Ccl2 receptor Ccr2 was increased in 13F3-treated
mice [11].
In macrophages, expression of VISTA is required for the
engulfment and uptake of apoptotic cells in vivo and in vitro
[8, 43]. VISTA is upregulated in a p53-dependent manner in
apoptotic cells and a homophilic interaction with VISTA on
macrophages facilitates efferocytosis [8]. A lack of VISTA on
either phagocytes or apoptotic cells impairs dead cell clear-
ance [8]. However, as mentioned, a homophilic interaction of
VISTA could not be replicated to date [19]. Concordantly,
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blocking VISTA on macrophages using a neutralizing anti-
body also reduces the uptake of neutrophils in vitro [43].
Many of the presented experiments are based on a generic
VISTA KO mouse model or systemically administered
VISTA-modulating antibodies. Therefore, it cannot be ex-
cluded that some of the observed changes in myeloid cells
are due to a lack of VISTA on other cell types as opposed to
a cell-intrinsic role of VISTA. However, most studies addi-
tionally used cell-specific in vitro assays to verify their results,
suggesting a cell-intrinsic function. Using conditional deple-
tion of VISTA in a cell-type-specific manner will be important
to further dissect the function of VISTA in myeloid cells
in vivo.
In summary, VISTA functions beyond being an NCR and
is involved in multiple aspects of the innate immune response
of myeloid cells.
Dual role of VISTA as receptor and ligand
VISTA has a large spectrum of expression and functions
across multiple tissues and cell types. This diverse function
and expression may in part be attributed to the dual role of
VISTA as a receptor and a ligand. However, despite major
efforts and hampered by the lack of optimal functional assays,
whether VISTA has a single or multiple ligands and receptors
remains in need of further clarification and verification.
Regarding the function of VISTA as an NCR, both ligand
and receptor activities on APC and T cells can lead to T cell
inhibition. VISTA-Ig fusion proteins and VISTA-
overexpressing A20 cells both reduce proliferation of anti-
CD3-stimulated T cells [6, 44]. Therefore, VISTA expressed
on APC can act as a ligand, and upon binding to a
counterreceptor on T cells, this leads to T cell inhibition.
Conversely, engaging VISTA expressed on naïve T cells can
also inhibit T cell activation, which has been shown in the
context of hepatitis [34] and GvHD in mouse models [7,
14]. As mentioned, treatment of mice with agonistic anti-
VISTA antibody (clone MH5A) activating VISTA signalling
protects mice against GvHD [14]. Passive transfer of wild-
type T cells into VISTA KO mice and subsequent anti-
VISTA treatment also reduced GvHD, demonstrating that
host cells are not involved in this protective effect [14].
Thus, VISTA as a receptor on T cells and as a ligand on T
cells as well as APC inhibits T cell activation and thereby
exerts its role as an NCR.
In myeloid cells, VISTA also acts as a receptor thereby
exerting functions beyond inhibition of T cell activation.
Overexpression of VISTA in human monocytes/
macrophages leads to spontaneous inflammatory cytokine se-
cretion, which is abrogated after deleting the cytoplasmic do-
main [10]. Although the cytoplasmic domain of VISTA does
not contain any immunoreceptor tyrosine-based signalling
motifs, multiple casein kinase 2 and phosphokinase C phos-
phorylation sites are present [17]. These data demonstrate that
engagement of VISTA onmyeloid cells results in downstream
cellular signalling through the cytoplasmic tail, which has
functional ramifications for the cell such as cytokine produc-
tion [10].
This dual role of VISTA as a receptor and ligand has im-
portant consequences for studying its function and the thera-
peutic potential of anti-VISTA antibodies. The effect of
VISTA KO and VISTA-targeted treatment must be studied
for individual cell types and with regard to VISTAs broad
functions.
VISTA in the CNS
Expression and function of NCR in peripheral immunity es-
pecially during cancer and autoimmunity are extensively stud-
ied and are beginning to be understood. In contrast, the phys-
iological and pathological functions of NCR in the CNS are in
its infancy, although NCR are likely involved in a variety of
CNS functions including communication with peripheral im-
mune cells. The extensive functional diversity of VISTA in
myeloid cells points towards functional relevance for VISTA
in CNS-resident myeloid cells: microglia. In this part, expres-
sion and function of NCR and particularly VISTA in microg-
lia are discussed.
Immune checkpoints in the CNS
In the CNS, various co-stimulatory and co-inhibitory recep-
tors are expressed by CNS-resident cells and during disease
also by infiltrating immune cells. In this review, we focus on
inhibitory immune checkpoints and particularly VISTA ex-
pression and function in CNS-resident cells.
Multiple inhibitory immune checkpoints are expressed by
mouse and human CNS-resident cells at least on mRNA level
with varying abundancies including A2AR, B7-H3, BTLA,
CTLA4, LAG3, NOX2, PD1, PDL1, PDL2, TIM3 and
VISTA (Fig. 1). Every major CNS cell type (neurons, oligo-
dendrocytes, microglia, astrocytes and endothelial cells) ex-
presses inhibitory immune checkpoints, but microglia express
the largest diversity (Fig. 1). Expression of many of these
inhibitory immune checkpoints is induced or upregulated dur-
ing inflammatory conditions including PD1, PDL1, PDL2 and
TIM3 [1].
Function and in-depth expression dynamics of the majority
of immune checkpoints have not been studied in detail in the
CNS. The best studied NCR in the CNS is PDL1 (also known
as CD274 and B7-H1), which is predominantly expressed by
microglia and neurons (Fig. 1). During inflammation, PDL1
expression is induced in astrocytes, oligodendrocytes [67] and
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endothelial cells [68] and upregulated in microglia [12] and
neurons. Upregulation or induction of PDL1 in microglia and
astrocytes during inflammation may limit CNS inflammation
and pathology by inhibition of T cell activation [69]. In EAE,
for example, responses of infiltrating PD1-expressing T cells
are suppressed by microglia PDL1 expression [70].
Conversely, deletion of PDL1 or PDL2 in mice reduces the
infarct volume after middle cerebral artery occlusion, due to
reduction of immune-activated microglia and infiltrating pe-
ripheral immune cells [71]. Hence, it is possible that expres-
sion of PDL1 has different functional consequences for differ-
ent cell types (T cells vs myeloid cells). In PDL1-deficient
mice, an increase in PD1 and PDL2 expression was detected
[71], suggesting a compensatory mechanism. Therefore, ge-
netic depletion of one NCR can likely be balanced by upreg-
ulation of functionally similar NCR.
TIM3 is a co-inhibitory receptor that suppresses T cell ac-
tivation. In microglia, TIM3 regulates inflammatory responses
such as iNOS production after exposure to glioma-
conditioned medium [72], suggesting that NCR have intrinsic
functions in microglia biology. In melanoma brain metastases,
microglia are the principal IDO-expressing cell type compared
with infiltrating immune cells [73]. IDO is an immunomodu-
latory enzyme that facilitates conversion of tryptophan to
kynurenine, resulting in antimicrobial and immunosuppres-
sive environments [74]. This high expression of IDO indicates
that microglia are potent immunomodulatory cells especially
during CNS diseases that include immune cell infiltration,
such as MS.
Expression of VISTA in the CNS
VISTA mRNA is expressed in whole brain tissue, but much
lower compared with thymus, spleen and lung [6]. To our
knowledge, there is only one study to date that focused on
VISTA expression in the CNS [12]. In that study, we demon-
strate that in the mouse and human CNS, VISTA is predom-
inantly expressed by microglia, which are the parenchyma
resident myeloid cells [12] (also shown in Fig. 1a, b).
During mouse and human development, microglia VISTA ex-
pression increases gradually with highest expression in adult
microglia [12, 75, 76]. VISTA expression levels in microglia
are comparable with well-established microglia markers such
as CX3CR1, TMEM119, P2RY12 and ITGAM (CD11B) [12,
47]. CNS myeloid cells (microglia and brain-border macro-
phages) express higher levels of VISTA than peripheral mye-
loid cells, and VISTA expression is higher in microglia com-
pared with perivascular macrophages (Fig. 1b). Interestingly,
after diphtheria toxin-induced ablation of microglia express-
ing diphtheria toxin receptor, VISTA expression is higher in
repopulated microglia than in bone marrow-derived microglia
(Fig. 1b). Together, these results suggest that microglia
VISTA expression is higher compared with peripheral mye-
loid cells, which express the highest levels of VISTA among
peripheral immune cells [6, 14, 20].
ATAC-seq data suggests that VISTA expression is regu-
lated by SPI1/PU.1 [12], a transcription factor essential for
microglia and myeloid cell biology. In mouse spinal cord
and brain, more than 95% of microglia (Cd11bposCd45int)
express VISTA, whereas only few Cd11bnegCd45neg cells ex-
press VISTA [12]. These VISTA positive non-microglia cells
are most likely endothelial cells, since endothelial cells ex-
press low but detectable mRNA levels of VISTA [12].
Furthermore, blood vessels are positive for VISTA in immu-
nohistochemical staining of mouse and human brain, which
underscores endothelial VISTA expression. RNA sequencing
data also suggests expression of VISTA by astrocytes; howev-
er, protein expression was not detectable by immunohisto-
chemical staining [12]. Expression dynamics and potential
function of VISTA during inflammation, ageing and CNS
diseases are further discussed below.
Fig. 1 Expression of VISTA and other inhibitory immune checkpoints in
mouse and human CNS during homeostasis. a Heatmap illustrates
mRNA levels as log2(FPKM) in different types of CNS cells, derived
from published mRNA sequencing data [45, 46]. b Log fold change
(logFC) of VISTA expression in microglia compared with other CNS
cells, myeloid cells, bone marrow-derived microglia and in different
CNS regions (Table 1). FPKM = fragments per kilobase million, logFC
= log2FoldChange, BM = bone marrow
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Potential functions of VISTA in microglia
Microglia are myeloid cells of the CNS and possess similar
functions as tissue macrophages such as antigen presentation,
phagocytosis, respiratory burst and release of cytokines and
chemokines [77]. As opposed to other tissue-macrophage sub-
sets, microglia also exhibit a range of CNS-specific functions
including synaptic pruning, and the release of neurotrophic as
well as neurotoxic factors [77]. During homeostasis, microglia
are constantly scanning their environment and are highly sen-
sitive and responsive towards any perturbations [77]. Hence,
the notion of resting microglia has become obsolete. Despite
major efforts, defining microglia functionality in the M1-M2
continuum has been unproductive and contentious [78]. The
function of VISTA in microglia and the CNS is unknown. In
this paragraph, potential functions of VISTA in microglia are
discussed based on known functions of VISTA in other mye-
loid cells (Fig. 2).
Since microglia are capable of presenting antigens and ex-
pressing other NCR, it is conceivable that VISTA as a ligand
also acts as an NCR in microglia, where it binds to a
counterreceptor on T cells leading to inhibition of T cell acti-
vation (Fig. 2). VISTA functioning as an NCR in microglia
might be of particular relevance for CNS-peripheral immunity
interactions (discussed below), which predominantly occur
during immune cell infiltration in CNS diseases such as MS.
In view of VISTA ligand functions as an NCR, it is intriguing
that microglia express VISTA at such high levels during
steady state, since peripheral immune cells including T cells
are sparse in healthy brain parenchyma. Therefore, it is likely
that in addition to inhibiting T cell activation, VISTA has a
function in microglia as a receptor.
In monocytes/macrophages, VISTA as a receptor is in-
volved in efferocytosis [8], cytokine production [10] and che-
motaxis [11]. Since microglia are functionally closely related
to monocytes/macrophages, it is possible that one or more of
these functions is also regulated by VISTA in microglia (Fig.
2). Particularly, the involvement of VISTA in efferocytosis
would be highly relevant for microglia. Microglia are respon-
sible for clearing cellular debris in the brain, especially during
development and disease [77] (Fig. 2). Furthermore, microglia
are involved in synaptic pruning (synaptophagy) [77], a spe-
cific form of phagocytosis to eliminate viable synapses, which
is required for learning and memory. VISTA as a receptor
might be involved in these processes, in view of its role in
phagocytosis in macrophages [8].
Microglia are highly capable of producing pro and anti-
inflammatory cytokines and chemokines upon receiving a
wide variety of stimuli [77]. The intracellular pathways lead-
ing to the production of these signalling molecules are mostly
conserved between microglia and other tissue macrophages.
Since overexpression of VISTA in vitro leads to spontaneous
Fig. 2 Potential functions of
VISTA in microglia and the effect
on CNS homeostasis and disease.
VISTA expressed on microglia
may act as a receptor and a ligand,
binding to proposed and
unknown ligands/receptors.
Based on VISTA function in
myeloid cells, VISTA may be




motility and chemotaxis. These
microglia functions are important
for maintaining CNS homeostasis
including synaptic pruning,
removal of metabolic waste and
cell debris and immune tolerance.
Furthermore, these potential
functions of VISTA in microglia
are essential during CNS disease,





and for tissue regeneration
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cytokine secretion (TNF, IL1β) in human monocytes [10],
and knockout of VISTA is associated with an altered
cytokine/chemokine profile (Ccl2, Il23) [38, 40–42], VISTA
may also be involved in microglia cytokine/chemokine
production.
VISTA as a receptor is not only involved in the production,
but also in the response to chemokines. Blocking VISTA in
mice leads to enhanced migratory capacity of monocytes in
response to Ccl2 in vitro [11]. Ccl2 in the CNS is produced by
astrocytes, microglia, endothelial cells [79] and can be pro-
duced by neurons during stress such as impairment of oxida-
tive metabolism [80]. Microglia express Ccr2 and respond to
Ccl2 by migrating and producing cytokines [79]. This re-
sponse can be both beneficial and detrimental as it leads to
clearance of debris, but also contributes to neuroinflammation
by production of pro-inflammatory cytokines [79, 80]. VISTA
could be involved in the microglia response/migration to Ccl2,
which would have ramifications particularly during CNS dis-
eases where Ccl2 production is increased such as MS, trau-
matic brain injury and stroke [79] (Fig. 2).
Roles of VISTA and other NCR
in CNS-peripheral immunity interactions
NCR are pivotal signalling molecules that aid in balancing
immune responses to limit autoimmunity while maintaining
an effective immune response. Therefore, it is important to
discuss the role of NCR and VISTA with regard to their direct
signalling capacity through cell-cell interactions, in this case,
the interaction between CNS and peripheral immunity. There
are two main types of CNS-peripheral immunity interactions:
indirect (e.g. through cytokines and other secreting signalling
molecules) and direct (cell-cell contact through receptors)
[81]. We will focus on direct interactions of glia and endothe-
lial cells with the peripheral immunity via NCR and VISTA.
The initial contact of peripheral immune cells with the CNS
is via endothelial cells, which directly interact with immune
cells. Endothelial cells can regulate the trans-migration of the
peripheral immune cells into the CNS, which is of particular
importance during CNS diseases such as MS [82]. Blocking
the adhesion of immune cells to the endothelium by
natalizumab blocking VLA4 emerged as an effective therapy
to limit neuroinflammation [83]. Endothelial cells are capable
of presenting antigens through MHC-II and can facilitate the
trans-migration of T cells into the brain parenchyma [84]. As
capable APC, endothelial cells also express a range of NCR
(Fig. 1) such as PDL1 and PDL2 which suppress T cell re-
sponses in vitro [85] and may inhibit T cell trans-migration.
VISTA as a ligand expressed by endothelial cells may provide
inhibitory signals to passing T cells as well, thereby fine-
tuning T cell reactivity in the CNS, which is of particular
importance in CNS diseases with immune cell infiltration
(e.g. MS). The function of VISTA in endothelial cells has
not been studied to date but should be investigated particularly
with regard to peripheral immune cell infiltration into the CNS
and antigen presenting capability of the endothelium.
Other CNS cell types that can actively communicate with
peripheral immune cells via direct contact are astrocytes and
microglia. Both cell types can express MHC-II (induced/up-
regulated during inflammation notably by interferons) and are
capable of presenting antigens to T cells [86], and both cell
types express NCR, as previously mentioned (Fig. 1).
Microglia PDL1 expression regulates T cell (re)activation in
the CNS during EAE [70, 87]. In the transgenic APP/PS1
(APPswe/PS1dE9) mouse model for Alzheimer’s disease, de-
pletion of microglia using a Csf1r inhibitor (PLX5622) results
in an increase in parenchymal T cell numbers and a reduction
of anti-inflammatory cytokines [88]. It is thus conceivable that
microglia provide inhibitory signals to T cells, which is essen-
tial to limit T cell (re)activation in the CNS. Functional evi-
dence on whether VISTA expressed by microglia has co-
inhibitory effects on T cell activation is lacking; however,
based on extensive characterisation of VISTA NCR functions
in other myeloid cells, it is highly likely that blocking or de-
pleting VISTA on microglia will enhance T cell (re)activation
in the brain.
VISTA in CNS diseases and aging
Microglia are involved in CNS diseases by mounting inflam-
matory responses, assisting in clearance of waste and
defending the CNS from intruder pathogens and toxic com-
pounds. As described above, expression of most NCR is
induced/upregulated in microglia and other CNS cell types
during inflammation and CNS disease, e.g. PDL1 [12].
VISTA expression, however, is decreased in microglia during
CNS inflammation and disease [12]. To expand on these ob-
servations, we analysed VISTA expression with focus on mi-
croglia in published mRNA sequencing datasets of multiple
CNS diseases and respective animal models including neuro-
degenerative diseases (NDD), MS, infection, stroke, glioblas-
toma (GBM) and aging. This analysis is summarized in Fig. 3
and discussed in more detail below.
Neurodegenerative diseases
NDD, including AD, frontotemporal dementia (FTD),
Parkinson’s disease (PD) and amyotrophic lateral sclerosis
(ALS), are progressive degenerative diseases of the CNS.
Hallmarks of NDD are the loss of neurons and neuroinflam-
mation. Microglia are the major source of neuroinflammation
in NDD and significantly contribute to development and pro-
gression of these diseases [89, 90]. However, microglia also
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phagocytose cellular debris and plaques that are formed in
many NDD, thereby facilitating clearance of waste. Hence,
microglia appear to have both beneficial and detrimental func-
tions in NDD.
In the AD mouse model 5XFAD and ALS model
SOD1G93A, microglia downregulate expression of homeo-
static genes, while upregulating genes involved in immune
activation and phagocytosis [52]. This NDD-associated mi-
croglia phenotype is also called disease-associated microglia
(DAM or MGnD) [52, 91, 92]. DAM microglia in both AD
and ALS models exhibit 2-fold reduced VISTA expression
(Fig. 3, Table 1). The decrease in microglia VISTA expression
is consistent across multiple AD mouse models including
5XFAD, APP/PS1 and PS2APP (Fig. 3, Table 1). In spinal
cord microglia from ALS SOD1G93A mice, VISTA expres-
sion is slightly upregulated in early stages, but decreased dur-
ing the end stage of disease (Fig. 3, Table 1). In tau mouse
models that carry P301L or P301S mutations associated with
FTD and PD, VISTA expression in microglia is also reduced
(Fig. 3, Table 1). Collectively, these data point towards VISTA
being regulated in microglia similar to homeostatic markers,
which are also decreased during microglia activation and in
NDD [90].
Although the function of VISTA in microglia remains un-
known, VISTA knockout in myeloid cells leads to decreased
phagocytosis and elevated production of cytokines [8, 38, 41].
Therefore, reduction in microglia VISTA expression during
NDD could have detrimental effects, as it might enhance neu-
roinflammation while inhibiting the clearance of cell debris
and waste.
Surprisingly, VISTA gene expression in bulk tissue from
AD and ALS mice and in post-mortem human AD tissue is
elevated (Fig. 3, Table 1). Endothelial cells express low levels
of VISTA in non-diseased conditions, but it is possible that
expression is upregulated during NDD. Furthermore, VISTA
expression might be induced in other CNS cell types in NDD,
which do not express VISTA under homeostatic conditions.
Together, VISTA expression by microglia is consistently
decreased in multiple models of NDD, which could have det-
rimental effects. However, bulk tissue gene expression data
indicates that other CNS cell types upregulate or induce
VISTA expression in these conditions, warranting further
investigation.
Multiple sclerosis
MS is a chronic demyelinating autoimmune disease of the
CNS characterised by formation of demyelinated areas or le-
sions that contain peripheral immune cell infiltrates dominated
by macrophages. The heterogeneous nature of MS manifests
in highly individual disease courses, a diversity of clinical
symptoms and the emergence of different types of lesions.
These lesions can be staged based on degree of demyelination
and inflammation [93, 94]. Based on studies using a wide
variety of EAEmodels, microglia are believed to be beneficial
during initial disease responses in order to resolve inflamma-
tion and promote tissue regeneration [95]. Later during the
disease, microglia may contribute to chronic neuroinflamma-
tion and neurodegeneration.
Microglia VISTA expression is reduced during all stages of
actively induced disease by MOG35-55 in CFA [12], and
VISTA knockout exacerbates EAE in a spontaneous TCR-
transgenic [13]. Cuprizone-feeding in mice is a model in
which chemical-induced death of oligodendrocytes leads to
demyelination and remyelination, and microglia immune-
Fig. 3 VISTA expression in CNS diseases and aging. Log fold change
(logFC) of VISTA expression in microglia or bulk CNS tissue during
disease compared with control (Table 1). DAM = disease-associated mi-
croglia, Homeo = homeostatic microglia, WT = wild-type, AD =
Alzheimer’s disease, NDC = non-demented control, MS = multiple
sclerosis, NAWM = normal-appearing white matter, LPS = lipopolysac-
charide, PBS = phosphate-buffered saline, LCMV = lymphocytic
choriomeningitis virus, SPF = specific-pathogen free, MFP2 =multifunc-
tional protein-2, tMCAO = transient middle cerebral artery occlusion,
GBM = glioblastoma
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activation in the absence of peripheral immune cell infiltrates.
VISTA expression in microglia is also reduced in this MS
mouse model (Fig. 3, Table 1). Furthermore, VISTA expres-
sion is decreased in chronic active MS lesions [12], jointly
suggesting a role for VISTA in MS.
Most MS lesions occur in white matter (WM); however,
grey matter (GM) lesions are frequent and are a hallmark of
MS. In MS WM, microglia VISTA expression is slightly de-
creased compared with WM of non-demented controls
(NDC), whereas no difference is evident in MS GM (Fig. 3,
Table 1).
One hallmark of MS lesions and EAE is the infiltration of
peripheral immune cells including macrophages and lympho-
cytes. More recently, neutrophils were also associated with
Table 1 VISTA expression in microglia, CNS diseases and ageing
Description Species Tissue Cell subset Condition logFC padj Reference
Microglia in
healthy CNS
Microglia vs other CNS cells Mouse Cortex Cd45+ Control 7.75 0.006 [46] a
Myeloid vs other CNS cells Human Temporal cortex CD45+ Control 3.05 0.001 [45] a
Microglia vs unsorted tissue Human Cortex CD11B+
CD45int
Control 4.06 0.000 [47]
Myeloid brain vs periphery Mouse Brain, peripheral
tissues







Control 10.00 1.000 [49] a
Repopulated microglia vs
BM-derived microglia
Mouse Brain Cd11b+Cd45int Control 1.58 0.001 [50] a





Cd11b+ Control 0.51 0.000 [51] a
Neurodegenerative
diseases
5XFAD DAM vs homeo Mouse Brain Cd45+ 5XFAD − 1.13 NA [52]
SOD1G93A DAM vs homeo Mouse Spinal cord Cd45+ SOD1G93A − 0.90 NA [52]
SOD1G93A 65d vs WT Mouse Spinal cord Cd11b+ SOD1G93A 0.49 NA [53]
SOD1G93A 100d vs WT Mouse Spinal cord Cd11b+ SOD1G93A 0.38 NA [53]
SOD1G93A end stage vs WT Mouse Spinal cord Cd11b+ SOD1G93A − 0.51 NA [53]
PS2APP vs WT Mouse Cortex Cx3cr1::Gfp+ PS2APP − 0.20 0.496 [54] a
5XFAD vs WT Mouse Brain Cd11b+Cd45int 5XFAD − 0.79 0.078 [55] a
APP/PS1 vs WT Mouse Cortex Cd11b+Cd45int APP/PS1 − 0.62 0.000 [56] a
hMAPT-P301L vs WT Mouse Hippocampus Cd11b+ hMAPT-p301L − 0.36 0.608 [54] a
hMAPT-P301S vs WT Mouse Hippocampus Cd11b+ hMAPT-p301S − 0.61 0.124 [54] a
PS2APP 13m vs WT (bulk) Mouse Cortex Bulk tissue PS2APP 0.97 0.000 [57] a
SOD1G93A 126d vs WT (bulk) Mouse Spinal cord Bulk tissue SOD1G93A 1.32 0.007 [58] a
AD vs NDC (bulk) Human Fusiform gyrus Bulk tissue AD 0.23 0.150 [54] a
Multiple
sclerosis
MS vs NDC (gray matter) Human Gray matter CD15-CD11B+ MS − 0.04 NA [59]
MS vs NDC (white matter) Human White matter CD15-CD11B+ MS − 0.23 NA [59]
Inactive lesion vs NAWM (bulk) Human White matter Bulk tissue MS 1.14 NA [60]
Active lesion vs NAWM (bulk) Human White matter Bulk tissue MS 1.10 NA [60]
Chronic active lesion vs NAWM
(bulk)
Human White matter Bulk tissue MS 0.63 NA [60]
Remyelinated lesion vs NAWM
(bulk)
Human White matter Bulk tissue MS 1.22 NA [60]
Cuprizone (12w) vs control Mouse Brain Cd11b+Cd45int Cuprizone − 1.28 0.424 [61] a
Infection LPS vs PBS Mouse Cortex Cd11b+ LPS − 2.14 0.000 [57] a
LPS vs PBS (SPF) Mouse Brain Cd11b+Cd45int SPF, LPS − 1.72 0.363 [62] a
LCMV vs PBS (SPF) Mouse Brain Cd11b+Cd45int SPF, LCMV 0.19 0.918 [62] a
Other diseases MFP2 knockout vs WT Mouse Brain Cd11b+Cd45int MFP2
knockout
− 0.87 0.091 [63] a
tMCAO vs sham Mouse Cortex Cd11b+Cd45int tMCAO − 0.93 0.414 [64] a
GBM vs control Mouse Brain, tumour Cd11b+ Glioma − 1.84 0.002 [65] a
GBM vs non-tumour Human Brain, tumour Microglia
(scRNAseq)
Glioma 0.08 NA [66]
Ageing 22m vs 4/12m (cerebellum) Mouse Cerebellum Cd11b+ Control − 0.38 0.161 [51] a
> 50 years vs < 50 years Human Cortex CD11B+
CD45int
Control 0.16 NA [47]
> 50 years vs < 50 years (bulk) Human Cortex CD11B+
CD45int
Control 1.00 NA [47]
a Data from myeloid brain expression meta-analysis [54]
BM bone marrow, ctx cortex, hippo hippocampus, DAM disease-associated microglia, Homeo homeostatic microglia, WT wild-type, AD Alzheimer’s
disease,MSmultiple sclerosis, tMCAO transient middle cerebral artery occlusion, SPF specific pathogen free, LPS lipopolysaccharide, LCMV lympho-
cytic choriomeningitis virus, MFP2 multifunctional protein-2, GBM glioblastoma, KO knockout, NA not available
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lesion formation and MS pathology [96]. A loss or reduction
of VISTA expression on microglia in MS/EAE may boost
(re)activation of infiltrating T cells in lesions, thereby exacer-
bating inflammation and tissue damage. Moreover, reduced
VISTA levels in microglia and infiltrating monocytes may
impair their phagocytic ability, which is important for clear-
ance of cellular and myelin debris early during the disease
[95]. The role of VISTA in microglia in MS/EAE might de-
pend on the stage of disease and the type of MS lesion, in-
cluding the lesion microenvironment and how microglia re-
spond to these environmental cues.
Microglia-specific gene expression in different types of
MS lesions has not been studied yet; however, data on bulk
tissue from different lesions is available. Here, VISTA expres-
sion is upregulated in all investigated types of lesions includ-
ing inactive, active, chronic active and remyelinated (Fig. 3,
Table 1). It remains conceivable that microglia VISTA expres-
sion is reduced, but this cannot be detected in bulk tissue when
other cell types upregulate/induce VISTA expression. As
discussed above, although endothelial VISTA expression is
low under homeostatic conditions, it might be upregulated
during non-homeostatic conditions. Furthermore, other CNS
cell types may induce VISTA expression, explaining elevated
VISTA levels in bulk tissue. VISTA is likely also expressed by
infiltrating immune cell subsets including neutrophils, lym-
phocytes and myeloid cells in MS lesions. VISTA is upregu-
lated at least in myeloid cells under inflammatory conditions
[10], which would also explain elevated VISTA levels in MS
lesions. It will be important to assess cell type-specific VISTA
expression in different types of MS lesions to dissect the role
of VISTA in microglia and other cell types during MS devel-
opment and progression.
Infection
Microglia express a range of pattern-recognition receptors
such as toll-like receptors (TLR), C-type lectin receptors and
NOD-like receptors, which allows them to sense and respond
to pathogen-associated and damage-associated molecular pat-
terns [97]. In the CNS, microglia are the major cell type ca-
pable of monitoring and defending the tissue from intruders
including bacteria and viruses. Upon response towards micro-
bial compounds such as LPS (TLR4), polyI:C (TLR3), β-
glucan (Dectin-1, TLR2/6), Pam3CSK4 (TLR1/2), VISTA ex-
pression decreases in mouse and rhesus macaque microglia
in vitro by 50–70% [12]. A similar decrease is observed in
mouse microglia 3/6/24 h after intraperitoneal LPS injection
[12] (Fig. 3, Table 1). Although VISTA expression is reduced
after LPS injection, it is not altered during infection with lym-
phocytic choriomeningitis virus (LCMV) by intracerebral in-
oculation (Fig. 3, Table 1).
The lack of studies on infections in relation to VISTA
biology in the CNS underscores that this important topic re-
mains largely unexplored.
Other CNS diseases and aging
By contributing to neuroinflammatory mechanisms, mi-
croglia are also involved in a range of other neurological
diseases including stroke, cancer and more. VISTA expres-
sion by microglia is reduced in almost all CNS disease
conditions including multifunctional protein-2 (MFP2)
knockout mice (Fig. 3, Table 1). MFP2 defects in humans
usually lead to severe developmental pathologies includ-
ing neonatal hypotonia, seizures, psychomotor retardation
and brain malformations [98]. In mice, MFP2 knockout
leads to Purkinje cell degeneration and neuroinflammation
[98].
During transient middle-cerebral artery occlusion
(tMCAO), which leads to stroke in mice, microglia VISTA
expression is reduced 2-fold (Fig. 3, Table 1). Although inhi-
bition of microglia activation during stroke leads to beneficial
outcomes, microglia activation is also necessary to counteract
neuronal death and enhance neurogenesis [99].
Microglia and macrophages are part of the tumour en-
vironment in GBM and promote tumour progression by
producing anti-inflammatory cytokines, immunosuppres-
sive molecules and angiogenic factors [100]. Although
microglia acquire a more immune-silencing phenotype
characterized by secretion of anti-inflammatory cytokines
and an upregulation of NCR, VISTA expression is reduced
in mouse microglia and unaltered in human microglia as-
sociated with GBM (Fig. 3, Table 1). A decrease in VISTA
expression may be beneficial for GBM, since knockout of
VISTA renders mice high resistance against glioma tu-
mours [34].
During aging, microglia are thought to become primed,
dystrophic and senescent, leaving them less responsive
and incapable of properly monitoring the CNS [101];
hence, microglia phenotypes associated with aging may
contribute to the development of NDD such as AD and
PD. Aged mouse cerebellar microglia exhibit reduced
VISTA expression compared with microglia from younger
mice (Fig. 3, Table 1). In humans, such a comparison is
more difficult due to limited availability of post-mortem
tissue from young individuals. However, VISTA expres-
sion is slightly increased in microglia from individuals >
50 years of age compared with < 50 years (Fig. 3,
Table 1). This increase is much more pronounced in bulk
tissue, which again supports the notion that other cell
types may upregulate or induce VISTA upon deficits in
CNS homeostasis.
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Therapeutic potential of VISTA in CNS disease
In oncology, immune checkpoint inhibitors (ICI) targeting
NCR such as PD1 and CTLA4 have emerged as effective
treatments that boost anti-tumour immunity. For autoimmuni-
ty, NCR-directed immunotherapy has more recently been ex-
plored in order to achieve inhibition of the immune system.
ICI are systemic drugs affecting not only the periphery, but
also the CNS. Therefore, ICI are used in the treatment of CNS-
associated tumours, but these drugs can also have neurological
side effects. VISTA is a more recently identified target for
immunotherapy and blocking or activating VISTA has been
proven effective inmouse models of cancer, inflammation and
autoimmunity. The understanding of VISTA biology in the
CNS is limited, and VISTA manipulation to enhance or mute
its activity may offer novel therapeutic approaches for CNS
diseases including GBM, NDD and MS.
Targeting VISTA in autoimmunity and cancer
In mouse studies, VISTA has successfully been used as a
target for immunotherapy in cancer and autoimmunity. The
twomain approaches that are used to block or enhance VISTA
signalling are employing immunoenhancing anti-VISTA an-
tibodies (antagonists) or immunosuppressive anti-VISTA an-
tibodies (agonists), respectively. In addition to antibodies,
small molecules or constructs can also be designed to target
VISTA, leading to enhanced or suppressed immunity.
In multiple mouse models of cancer, an immunoenhancing
anti-VISTA antibody (clone 13F3) leads to a reduction in
tumour size and increased overall survival [102]. Blocking
VISTA using immunoenhancing antibodies leads to increased
infiltration of tumour-specific T cells, a decrease in MDSC
numbers and suppressive capacity and a decrease in tumour-
specific Tregs [102]. Using these immunoenhancing anti-
VISTA antibodies in mouse models of autoimmunity includ-
ing EAE [6] and murine lupus nephritis [11] exacerbates
disease.
Immunosuppressive anti-VISTA antibodies reduce the se-
verity of inflammatory disease in mice including autoimmu-
nity. GvHD is prevented when targeting VISTA on donor T
cells using an immunosuppressive anti-VISTA antibody [14].
Using this immunosuppressive antibody (clone MH5A or
8G8), disease severity of experimental asthma [41], lupus,
hepatitis, psoriasis and arthritis [7] are reduced, and autoim-
munity in systemic and discoid lupus erythematosus is allevi-
ated [35].
In summary, VISTA can be used as a therapeutic target for
both enhancing the immune response in case of cancer and
inhibiting the immune response during inflammation and
autoimmunity.
Immunotherapy in the CNS
Immunotherapy using ICI is currently established as an effec-
tive treatment against several cancer types, and targeting im-
mune checkpoints is more recently being explored as new
treatment options for autoimmune diseases such as rheuma-
toid arthritis and MS. Studies mainly focus on the effects of
immunotherapy on peripheral immunity; however, evidence
strongly suggests that ICI affect the CNS as well.
Currently, there is no FDA-approved immunotherapy for
GBM, but initial preclinical studies have yielded some en-
couraging results [3]. Since GBM tumour cells and infiltrating
T cells express a range of NCR, targeting these checkpoints
may boost the anti-tumour immunity. In CNS metastatic dis-
eases, ICI targeting PD1 (pembrolizumab, nivolumab) and
CTLA4 (ipilimumab) have been shown to slow down progres-
sion or reduce tumour size [4].
Immunotherapy may not only be beneficial in CNS-
associated tumours, but also in NDD and MS. In AD, neuro-
i n f l a mm a t i o n i s a s s o c i a t e d w i t h i n c r e a s e d
hyperphosphorylated tau burden and microglia-mediated re-
cruitment of peripheral immune cells can help in clearing am-
yloid β plaques [103]. Anti-PD1 antibody therapy facilitates
clearance of amyloid β and improves cognitive performance
in ADmice [104]. However, conflicting data exist that suggest
there is no effect of anti-PD1 therapy in AD [28]. Currently,
there are more than 10 FDA-approved immunomodulatory
therapies for MS [105]. These drugs interfere with peripheral
immune cell trafficking to the CNS, deplete subsets of im-
mune cells or modulate immune signalling pathways; howev-
er, immune checkpoints are not used as a target for MS im-
munotherapy yet. Agonistic antibodies targeting NCR such as
VISTA may enhance immune inhibition signals and could
potentially present an effective treatment for MS.
Interestingly, ICI used in oncology have adverse effects on
the CNS. Nivolumab treatment of melanoma induced sponta-
neous, reversible CNS demyelination in a patient [106]. ICI-
treated patients are also more susceptible to developing other
CNS diseases including paraneoplastic neurological symp-
toms, encephalitis, MS and hypophysitis, an inflammation of
the pituitary gland [1]. In melanoma patients treated with ICI,
these neurological adverse events occur in 1% (anti-CTLA4),
3% (anti-PD1) or 14% (anti-CTLA4 and anti-PD1) of the
population [1]. These complications are likely caused by aug-
mented immune responses leading to neurotoxicity. However,
it is incompletely understood whether the ICI-associated CNS
adverse effects and beneficial effects of ICI on CNS-
associated tumours are mediated indirectly via infiltrating im-
mune cells, directly by therapeutic antibodies gaining access
into the CNS parenchyma at meaningful concentrations or by
both. Since the BBB is compromised during MS and many
CNS-associated tumours, it is highly likely that ICI can act on
CNS-resident cells directly. Therefore, studying NCR
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expression and function in CNS-resident cells is crucial to
developing ICI therapies for CNS diseases and to predict
and mechanistically understand CNS adverse events.
Approaches to modulate VISTA in CNS
disease
Based on effectiveness of targeting VISTA in cancer and au-
toimmunity in mice and the use of ICI in CNS-associated
tumours and NDD, it is conceivable that VISTA may offer a
novel therapeutic target for treating CNS disease.
When targetingVISTA as a therapeutic strategy to treat NDD,
CNS-associated tumours or MS, it is important to consider the
complex expression dynamics and functions of VISTA. Using
monoclonal antibodies against VISTA will not only target vari-
ous peripheral immune cells (APC, neutrophils, T cells), but also
microglia and CNS endothelial cells. Research has been focused
on the function of VISTA in peripheral immune cell subsets,
whereas there is no knowledge on the effects in the CNS of
targeting VISTA using monoclonal antibodies.
Regarding the potential function of VISTA in the CNS,
multiple functional outcomes of VISTA modulation are plau-
sible. Targeting VISTA on endothelial cells may be a viable
option to inhibit or enhance T cell activation during MS or
NDD and cancer, respectively. In mice, VISTA knockout en-
hances anti-glioma responses in mice [34]. During MS, pe-
ripheral immune cell infiltration may be reduced upon enhanc-
ing VISTA signalling in endothelial cells. Microglia are APC
and responsible for (re)activation of T cells in the CNS.
Modulating VISTA on microglia may have similar effects as
on endothelial cells. However, in microglia, VISTA may also
be involved in phagocytosis, cytokine response and chemo-
taxis. These potential functions make it difficult to predict the
outcome of modulating VISTA during peripheral and CNS
disease. Using anti-VISTA antibodies systemically may affect
microglia function unpredictably. It is therefore important to
further dissect VISTA function in microglia in order to under-
stand potential CNS responses to VISTA modulation. On the
other hand, the large variety of functions that VISTA has in
myeloid cells and potentially microglia may also open up
treatment possibilities. For example, antibodies targeting dif-
ferent VISTA epitopes may have distinct functional
consequences.
Concluding remarks
VISTA represents an NCR with unique characteristics which
is expressed predominantly by microglia in the CNS.
Expression of VISTA is differentially regulated in ageing,
neuroinflammation and multiple CNS diseases including neu-
rodegeneration, stroke and cancer. Effective targeting of
VISTA in cancer and autoimmunity opens wide possibilities
to modulate VISTA a a therapeutic strategy in CNS disease.
However, more knowledge on the functions of VISTA in the
CNS and the effects of systemic VISTA modulation on the
CNS is necessary to evaluate the therapeutic potential of
targeting VISTA in CNS diseases. VISTA’s roles in microglia
and the CNS are currently only beginning to be explored;
hence, we have formulated remaining open questions in Box
1. Answering these questions will provide insights into the
function of VISTA in microglia and in CNS disease, which
will potentially yield novel therapeutic strategies and mecha-
nistic insights into CNS homeostasis and disease.
Box 1. Seven open questions on VISTA in the CNS
1) What is the function of VISTA in microglia?
In myeloid cells, VISTA is involved in inhibition of T-cell activation, cytokine response, phagocytosis, 
and chemotaxis. Similar functions may also be attributed to VISTA in microglia.
2) What is the function of VISTA in endothelial cells?
Brain endothelial cells express low levels of VISTA. Since endothelial cells are involved in antigen 
presentation and cell migration into the CNS, VISTA may play a role in communication of 
endothelial cells with peripheral immune cells particularly during diseases such as MS.
3) Can VISTA expression be induced in other CNS-resident cells?
In non-diseased CNS tissue, VISTA is predominantly expressed by microglia and to lesser extent 
endothelial cells. Other NCR are known to be upregulated or induced during inflammation in other 
CNS cell types. Although VISTA expression is decreased in microglia during disease, bulk tissue 
VISTA expression is increased, suggesting induction or upregulation of VISTA on other CNS cell 
types.
4) Which cell types express VISTA in CNS diseases and specifically in distinct MS lesion types?
Microglia and endothelial cells express VISTA, but other CNS-resident cells potentially induce 
VISTA expression in disease, which is currently unknown. During CNS disease and particularly MS, 
where peripheral immune cells infiltrate the CNS, VISTA expression by different cell types and 
subsets should be dissected to understand the role of VISTA in neuroinflammation.
5) What are functional binding partners of VISTA?
Multiple VISTA binding partners have been proposed, however, many of these counterreceptors 
could not be replicated in other studies. To elucidate VISTA biology and develop VISTA-targeted 
treatment strategies, it will be essential to identify and replicate potential binding partner(s).
6) Does modulating VISTA using immunotherapy affect the CNS?
Preclinical studies are investigating the therapeutic potential of targeting VISTA in cancer and 
autoimmunity. Neurological adverse events after blocking other NCRs (PD1, CTLA4) in patients 
have been reported. Currently, it is unknown whether targeting VISTA can affect the CNS, or 
modulate CNS disease progression.
7) How can we modulate VISTA during CNS diseases as a therapeutic strategy?
Several therapeutic strategies to target VISTA in CNS disease are conceivable. Using monoclonal 
antibodies or small molecules, VISTA signalling could be enhanced or suppressed to treat CNS-
associated tumours, NDD, or MS. Research on possibilities to target VISTA in CNS disease is 
lacking.
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PD1 homologue; PS1, Presinilin 1; PSGL1, P-selectin glycoprotein li-
gand 1; SOD1G93A, Superoxide dismutase 1 mutation G93A; SPF,
Specific-pathogen free; TCR, T cell receptor; TIM3, T cell immunoglob-
ulin domain and mucin domain 3; TLR, Toll-like receptor; tMCAO,
Transient middle cerebral artery occlusion; TMEM119, Transmembrane
protein 119; TNF, Tumour necrosis factor; TREM2, Triggering receptor
expressed on myeloid cells 2; VISTA, V-type immunoglobulin domain-
containing suppressor of T cell activation; VSIG, V-set and Ig domain-
containing protein; WM, White matter; WT, Wild-type
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